Quality of life in patients with metastatic renal cell carcinoma: The importance of patient-reported outcomes

Cancer Treatment Reviews

Volumn 35, Issue 8, 2009, Pages 733-737

  Cella, David ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Axitinib; Everolimus; Metastatic renal cell carcinoma; Patient reported outcomes; Quality of life; Sorafenib; Sunitinib; Targeted therapy; Temsirolimus

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; MEDROXYPROGESTERONE ACETATE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANEMIA; ANOREXIA; ASTHENIA; BLEEDING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; FATIGUE; FEVER; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PROGNOSIS; QUALITY OF LIFE; RASH; REVIEW; SELF REPORT; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HEALTH STATUS; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; KIDNEY NEOPLASMS; PATIENT SATISFACTION; PYRIDINES; PYRROLES; QUALITY OF LIFE; SIROLIMUS; TREATMENT OUTCOME;

EID: 70449718833     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.07.003     Document Type: Review

References (35)

1. Ljungberg B., Hanbury D., and Kuczyk M. Renal cell carcinoma guideline. Eur Urol 51 (2007) 1502-1510
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer v.1.2008. National Comprehensive Cancer Network: http://www.nccn.org/professionals/physician_gls/PDF/kidneypdf [serial online] 2008. URL: http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf.
3. Godley P., and Taylor M. Renal cell carcinoma. Curr Opin Oncol 13 (2001) 199-203
4. Gupta K., Miller J.D., Li J.Z., Russell M.W., and Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34 (2008) 193-205
5. Sachdeva K, Makhoul I, Javeed M, Curti B. Renal cell carcinoma. eMedicine [serial online] 2006. http://www.emedicine.com/MED/topic2002.htm:1-23 URL: http://www.emedicine.com/MED/topic2002.htm.
6. Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews 2004; 3: Art. No.: CD001425. doi:10.1002/14651858. CD001425.pub2.
7. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
8. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
9. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
10. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
11. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol (2009) [Epub ahead of print 10.1200/JCO.2008.20.1293]
12. Brown M.L., Lipscomb J., and Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health 22 (2001) 91-113
13. Wagner L.I., Wenzel L., Shaw E., and Cella D. Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions. J Clin Oncol 25 (2007) 5058-5062
14. Harding G., Cella D., Robinson Jr. D., Mahadevia P.J., Clark J., and Revicki D.A. Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index. Health Qual Life Outcomes 5 (2007) 34-45
15. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353 (1999) 14-17
16. Cella D.F., Tulsky D.S., Gray G., et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11 (1993) 570-579
17. Webster K., Cella D., and Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1 (2003) 79
18. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
19. Bacik J., Mazumdar M., Murphy B.A., et al. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 13 (2004) 137-154
20. de Boer A.G., van Lanschot J.J., Stalmeier P.F., et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?. Qual Life Res 13 (2004) 311-320
21. EuroQol. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16 (1990) 199-208
22. Cella D., Yount S., Du H., et al. Development and validation of the functional assessment of cancer therapy-kidney symptom index (FKSI). J Support Oncol 4 (2006) 191-199
23. Cella D., Yount S., Brucker P.S., et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 10 (2007) 285-293
24. Cella D., Li J.Z., Cappelleri J.C., et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 26 (2008) 3763-3769
25. Bayer Heathcare AG. Nexavar, Summary of product characteristics; 2007.
26. Bukowski R., Szczylik C., Stadler W., Simantov R., and Shan M. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 25 18S (2007) 240s [Abstract 5023 (abstr)]
27. Bukowski R., Cella D., Gondek K., and Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30 (2007) 220-227
28. Szczylik C, Cella D, Eisen T, et al. Comparison of kidney cancer symptoms and quality of life (QoL) in renal cell cancer (RCC) patients (pts) receiving sorafenib vs interferon-a (IFN). In: Poster presented at the 44th annual meeting of the American Society of Clinical Oncology, Chicago, Illinois, 2008; [Abstract 9603. Ref Type: Unpublished Work].
29. Wyeth Pharmaceuticals, Inc. Torisel summary of product characteristics; 2007.
30. Parasuraman P., Hudes G., Levy D.E., Strahs A., Moore L., and DeMarinis R. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-a (IFN) or the combination of IFN+TEMSR. J Clin Oncol 25 18S (2007) 247S [abstract 5049 (poster presentation) (abstr)]
31. Rixe O., Bukowski R.M., Michaelson M.D., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8 (2007) 975-984
32. Trask P.C., Bushmakin A.G., Cappelleri J.C., Bycott P., Liau K., and Kim S. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol 47 (2008) 843-851
33. Amato R., Misellati A., Khan M., and Chiang S. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 24 18S Part 1 (2006) 224s-4530
34. Jac J., Giessinger S., Khan M.A., et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol: Official J Am Soc Clin Oncol 25 (2007) [Ref Type: Unpublished Work]
35. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449-456